General Announcement::Glenmark interim data on Favipiravir supports its safety in Covid19 patients

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
08-Jun-2021 20:27:54
Status
New
Announcement Sub Title
Glenmark interim data on Favipiravir supports its safety in Covid19 patients
Announcement Reference
SG210608OTHRIHSF
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
08/06/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark s interim data from PMS Study on Favipiravir supports its safety and effectiveness in real world settings with no new safety signals or concerns in Covid19 patients

Attachments

SGX PR 08062021.pdf
Total size =1105K